


VENTANA PD-L1 (SP263)

Rabbit Monoclonal Primary Antibody

The VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody empowers you to evaluate the expression of PD-L1 protein using the OptiView DAB IHC Detection Kit.



VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody staining of non small cell lung cancer (NSCLC) with membranous and cytoplasmic staining of the tumor cells, and immune cells staining within the stroma.

About VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody

VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody is a rabbit monoclonal primary antibody produced against programmed death-ligand 1 (PD-L1) also known as B7 homolog 1 (B7-H1) or CD274. It recognizes a transmembrane bound glycoprotein that has a molecular mass of 45–55 kDa. This antibody produces membranous and/or cytoplasmic staining.

Intended Use

VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody is intended for laboratory use in the detection of the PD-L1 protein in formalin-fixed, paraffin-embedded tissue. It is intended to be stained with BenchMark IHC/ISH instruments. It is indicated as an aid in the assessment of PD-L1 expression in human tissues.

About PD-L1

PD-L1 is a transmembrane protein that downregulates immune responses through binding to its two receptors programmed death-1 (PD-1) and B7-1 (CD80).¹ PD-1 is an inhibitory receptor expressed on T cells following T-cell activation, which is sustained in states of chronic stimulation such as in chronic infection or cancer.² Binding of PD-L1 with PD-1 inhibits T cell proliferation, cytokine production, and cytolytic activity, leading to the functional inactivation or exhaustion of T cells. CD80 is a molecule expressed on antigen presenting cells and activated T cells. PD-L1 binding to CD80 on T cells and antigen presenting cells can mediate downregulation of immune responses, including inhibition of T-cell activation and cytokine production.³ PD-L1 expression has been observed in immune cells and tumor cells.^{4,5} Aberrant expression of PD-L1 on tumor cells and tumor associated immune cells has been reported to impede anti-tumor immunity, resulting in immune evasion.^{2,5} Therefore, interruption of the PD-L1/PD-1 pathway represents an attractive strategy to reinvigorate tumor-specific T cell immunity suppressed by the expression of PD-L1 in the tumor microenvironment.

PD-L1 in Cancer

PD-L1 is expressed in a broad range of cancers including lung, melanoma, urothelial, ovarian, and colorectal cancer. Prevalence of PD-L1 expression has been reported from 12% to 100% depending on the tumor type, anti PD-L1 clone and cutoff for positivity.⁶

Ordering Information

VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody

Catalog Number	790-4905 [07494190001]
Quantity	50 tests
Positive control	Placenta
Species	Rabbit
Localization	Membranous and/or Cytoplasmic

Automation: optimized for use on all VENTANA BenchMark IHC/ISH staining instruments

Detection: optimized with OptiView DAB IHC Detection Kit (760-700) [06396500001]

Our lung portfolio helps you deliver diagnostic confidence

Product name*	Catalog Number
p40 (BC28) Mouse Monoclonal Primary Antibody	790-4950 [07394420001]
CONFIRM Thyroid Transcription Factor-1 (8G7G3/1) Mouse Monoclonal Primary Antibody	790-4398 [05479312001]
Thyroid Transcription Factor-1 (SP141) Rabbit Monoclonal Primary Antibody	790-4756 [06640613001]
Cytokeratin 5/6 (D5/16B4) Monoclonal Primary Antibody	790-4554 [06478441001]
Napsin A (MRQ-60) Mouse Monoclonal Primary Antibody	760-4867 [07047720001]
Napsin A (polyclonal)	760-4446 [05973805001]
VENTANA ALK (D5F3) CDx Assay - US only	790-4796 [06687199001]
VENTANA ALK (D5F3) Rabbit Monoclonal Primary Antibody - ex-US only	790-4794 [06679072001]

*All antibodies contain 50 tests

References

1. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. *Annu Rev Immunol.* 2008;26:677-704.
2. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. *Cancer Immunol Immunother.* 2007;56(5):739-745.
3. Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T-cell responses. *Immunity.* 2007;27(1):111-122.
4. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. *Nat Med.* 1999;5(12):1365-1369.
5. Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. *J Clin Oncol.* 2016;34(26):3119-3125.
6. Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. *Mol Cancer Ther.* 2015;14(4):847-856.

VENTANA, BENCHMARK, and OPTIVIEW are trademarks of Roche.
All other product names and trademarks are the property of their respective owners.

© 2019 Roche MC-US-00014-0419

Roche Diagnostics Corporation
9115 Hague Road
Indianapolis, Indiana 46256

diagnostics.roche.com